Profound Medical Corp
$ 7.78
5.07%
26 Feb - close price
- Market Cap 268,568,000 USD
- Current Price $ 7.78
- High / Low $ 7.82 / 7.45
- Stock P/E N/A
- Book Value 1.06
- EPS -1.32
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.62 %
- ROE -1.25 %
- 52 Week High 8.95
- 52 Week Low 3.76
About
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Analyst Target Price
$12.35
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-02 | 2023-08-09 | 2023-05-10 | 2023-03-07 |
| Reported EPS | 0.26 | -0.52 | -0.36 | -0.2 | -0.38 | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 | -0.32 | -0.46 |
| Estimated EPS | -0.38 | -0.27 | -0.2825 | -0.3225 | -0.3 | -0.29 | -0.3 | -0.32 | -0.33 | -0.34 | -0.34 | -0.36 |
| Surprise | 0.64 | -0.25 | -0.0775 | 0.1225 | -0.08 | 0.01 | 0.04 | -0.1 | 0.07 | -0.01 | 0.02 | -0.1 |
| Surprise Percentage | 168.4211% | -92.5926% | -27.4336% | 37.9845% | -26.6667% | 3.4483% | 13.3333% | -31.25% | 21.2121% | -2.9412% | 5.8824% | -27.7778% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PROF
2026-02-26 20:53:04
Profound Medical (PROF) is projected to report a year-over-year decline in earnings for Q4 2025, despite an anticipated increase in revenues. The company's EPS is expected to be a loss of $0.27 per share, with revenues reaching $7.65 million. While the Most Accurate Estimate is higher than the Zacks Consensus Estimate, leading to an Earnings ESP of +11.11%, a Zacks Rank of #4 makes it difficult to predict an earnings beat conclusively.
2026-02-22 04:12:36
This report provides risk-controlled trading plans for Profound Medical Corp. (PRN:CA) with specific buy and short targets and stop losses. It includes updated AI-generated signals and ratings for various terms (Near, Mid, Long) which are all currently "Weak." The article also lists an extensive archive of recent reports related to PRN:CA.
2026-02-16 10:57:43
This article provides a strategic market analysis for Profound Medical Corp. (PRN:CA), with trading plans, AI-generated signals, and recent ratings. The analysis suggests weak ratings across near, mid, and long terms for February 16. It also lists numerous past articles offering trading insights and reports for the company.
2026-02-13 13:27:43
Profound Medical Corp. (TSE:PRN) shares fell 27% recently, bringing their annual return to a 5.7% loss. Despite the significant drop, the company's price-to-sales (P/S) ratio of 15.8x remains in line with the Medical Equipment industry's median of 13.8x, which is curious given its projected revenue growth of 99% per year over the next three years, compared to the industry's 115%. This suggests investors might be overlooking the company's relatively weaker growth outlook, posing a potential risk if the P/S ratio adjusts to reflect these lower expectations.
2026-02-12 21:58:11
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Following the release, company management will host a conference call at 4:30 p.m. ET to discuss the results and business developments. The call details and a link to live registration are provided for interested parties.
2026-02-12 13:58:11
Profound Medical has been awarded INOVAIT's 2025–2026 Mount Logan Award for its significant advancements and international recognition of the TULSA Procedure™ for prostate disease. The TULSA-PRO system, developed in Canada, offers a precise, minimally invasive treatment for prostate cancer and BPH, utilizing real-time MRI and robotically controlled ultrasound to preserve patient quality of life. The company aims for widespread global commercialization and is expanding its sales and distribution efforts.
